// App-Quantinova.ai

4201 : Combination of palbociclib with enzalutamide shows in vitro activity in RB-proficient and androgen receptor-positive triple-negative breast cancer cells

Researchers

Presenter

  • Ling-Ming Tseng

Principal Investigators

  • Tzu-Ting Huang

  • Chun-Teng Huang

  • Ka-Yi Lau

  • Chun-Yu Liu

  • Chung-Wai Shiau

  • Kuen-Feng Chen

Medical Centers

  • Yang-Ming Branch of Taipei City Hospital, Taipei, Taiwan

  • National Yang-Ming University, Taipei, Taiwan

  • National Taiwan University Hospital, Taipei City, Taiwan

Locations

  • Taiwan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • Palbociclib

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved